BIOMAT Database Logo BIOMAT Database Logo

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. 1993

A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011714 Pyrans Pyran
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014520 Urethane Antineoplastic agent that is also used as a veterinary anesthetic. It has also been used as an intermediate in organic synthesis. Urethane is suspected to be a carcinogen. Ethyl Carbamate,Urethan,Carbamate, Ethyl
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
SYNTHESIS AND OPTICAL RESOLUTION OF HIGH AFFINITY P2-LIGANDS FOR HIV-1 PROTEASE INHIBITORS.
January 1995, Tetrahedron letters,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
March 1998, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.
February 2010, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.
December 2015, Organic & biomolecular chemistry,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
August 2011, Journal of medicinal chemistry,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
October 2008, Organic & biomolecular chemistry,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors.
June 2011, ACS medicinal chemistry letters,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
September 2007, Journal of medicinal chemistry,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
June 2011, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and S P McKee, and T T Duong, and T A Lyle, and J C Chen, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
April 2006, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!